Drugs / CCH-aaes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05419505 | Jun 2022 → Jan 2023 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03526549 | Apr 2018 → Oct 2021 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04677712 Comparator | Dec 2020 → Jun 2021 | cellulitis, panniculitis and localized lipodystrophy | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CCH-aaes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04677712 ↗ |
| Modality | Protein / enzyme biologic | “Biological: CCH-aaes” NCT03526549 ↗ |
| Route | Subcutaneous | “administered CCH-aaes by subcutaneous injection” NCT04677712 ↗ |